Sharada Kolekar

A drug targeting only p110α can block phosphoinositide 3-kinase signalling and tumour growth in certain cell types

Stephen M. F. Jamieson, Jack U. Flanagan, Sharada Kolekar et al. · Biochemical Journal · 2011 · 170 citations · Full text

Tumour Growth, Cancer Biology, Responsive Cell Lines +21

Synthesis and Biological Evaluation of Novel Analogues of the Pan Class I Phosphatidylinositol 3-Kinase (PI3K) Inhibitor 2-(Difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1<i>H</i>-benzimidazole (ZSTK474)

Gordon W. Rewcastle, Swarna A. Gamage, Jack U. Flanagan et al. · Journal of Medicinal Chemistry · 2011 · 103 citations · Full text

Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth

Melanie Sweetlove, Emma Wrightson, Sharada Kolekar et al. · Frontiers in Oncology · 2015 · 77 citations · Full text

Cell Proliferation, Tumor Biology, Mek Inhibitors +18

Novel pyrazolo[1,5-a]pyridines as p110α-selective PI3 kinase inhibitors: Exploring the benzenesulfonohydrazide SAR

Jackie D. Kendall, Anna C. Giddens, Kit Yee Tsang et al. · Bioorganic & Medicinal Chemistry · 2011 · 35 citations · Full text

Molecular Pharmacology, Medicinal Chemistry, Benzenesulfonohydrazide Sar +10

Diverse mechanisms activate the PI 3-kinase/mTOR pathway in melanomas: implications for the use of PI 3-kinase inhibitors to overcome resistance to inhibitors of BRAF and MEK

Khanh Bao Tran, Sharada Kolekar, Anower Jabed et al. · BMC Cancer · 2021 · 35 citations · Full text